Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. HSD17B13 as a promising therapeutic target against chronic liver disease

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Tarik Asselah
  • Hendrik Reesink
  • Jan Gerstoft
  • Victor de Ledinghen
  • Paul J Pockros
  • Michael Robertson
  • Peggy Hwang
  • Ernest Asante-Appiah
  • Janice Wahl
  • Bach-Yen Nguyen
  • Eliav Barr
  • Rohit Talwani
  • Lawrence Serfaty
Vis graf over relationer

BACKGROUND & AIMS: The aim of this integrated analysis was to assess the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected participants enrolled in the Phase 2/3 clinical programme with elbasvir/grazoprevir.

METHODS: Treatment-naïve and treatment-experienced participants 18 years of age or older with chronic HCV GT4 infection and baseline HCV RNA ≥10 000 IU/mL were included in the analysis. The analysis population was the full analysis set (FAS; all participants who received at least 1 dose of study medication) and a total of 155 HCV GT4 participants were evaluated. The primary endpoint was sustained virologic response at week 12 (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the completion of study therapy).

RESULTS: Overall, among GT4-infected participants treated with 12 or 16 weeks of elbasvir/grazoprevir ± ribavirin, the SVR12 efficacy rates were 96.4% (107/111) in treatment-naïve participants and 88.6% (39/44) in treatment-experienced participants. The SVR12 rates were 96.0% (97/101) in treatment-naïve participants treated with 12 weeks of elbasvir/grazoprevir and 100% (8/8) in treatment-experienced participants treated with 16 weeks of elbasvir/grazoprevir plus ribavirin. Efficacy was not impacted by GT4 subtype.

CONCLUSIONS: The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.

TidsskriftLiver international : official journal of the International Association for the Study of the Liver
Udgave nummer9
Sider (fra-til)1583-1591
Antal sider9
StatusUdgivet - sep. 2018

ID: 56396359